Reduced thyrotropin in euthyroid goitrous patients suggesting subclinical hyperthyroidism

Cardiovascular system and endogenous subclinical hyperthyroidism treatment: The time has come

“…Endogenous subclinical hyperthyroidism has also subdivided into grade I (TSH in the 0.1-0.4 mU/l range) and grade II (TSHb 0.1 mU/l) [16] and it is seen in patients with autonomously functioning thyroid nodule or multinodular goiter [14][15][16]18], Graves' disease [19], various forms of thyroiditis [20], representing a common disease in areas of iodine insufficiency [17,21]. It could have a high prevalence rate [22] but its effective relative prevalence remains still unclear [19,23], even if it has been suggested that it is between 0.7 and 7% or higher, and it is inversely correlated with the population's iodine intake [24,25]. Its prevalence is also related to the degree of TSH suppression, with the age of the population studied being higher in subjects above the age of 60-70 years with low serum TSH levels [24,25].…”

Endogenous subclinical hyperthyroidism and cardiovascular system: Time to reconsider?

“…Endogenous subclinical hyperthyroidism is a thyroid metabolic state in patients with autonomously functioning thyroid nodule or multinodular goiter [6],various forms of thyroiditis [7], in areas with endemic goiter and particularly in elderly subjects [8]. Endogenous sublinical hyperthyroidism could have a high prevalence rate [9] but its effective relative prevalence remains still unclear [10]. Endogenous subclinical hyperthyroidism is currently the subject of numerous studies and it yet remains controversial particularly as it relates to its treatment [7,11] and to cardiovascular impact [4,[12][13][14][15][16] nevertheless endogenous subclinical hyperthyroidism has been reported to be associated with decreased left ventricular end diastolic volume, increased left ventricular mass, reduced exercise performance [6,11], increased heart rate [6] and induction of arrhythmias [6] including atrial fibrillation [6,[17][18][19][20] and atrial flutter [21,22].…”

Acute myocardial infarction without significant coronary stenoses associated with endogenous subclinical hyperthyroidism

“…Nowadays, there is growing interest regarding endogenous sublinical hyperthyroidism and the cardiovascular system [15,16]. Endogenous sublinical hyperthyroidism could have a high prevalence rate [17] but its effective relative prevalence remains still unclear [18] and yet it remains controversial particularly as it relates to its treatment [18,19] and to cardiovascular impact [4,16,[20][21][22][23][24] nevertheless endogenous subclinical hyperthyroidism has been reported to be associated with decreased left ventricular end diastolic volume, increased left ventricular mass, reduced exercise performance [20,25], increased heart rate [25] and induction of arrhythmias [25] including atrial fibrillation [6][7][8]12,25] and atrial flutter [13,14]. Furthermore it has also been reported, that in patients with subclinical hyperthyroidism, increased factor X activity [18], increased von Willebrand factor [26] and levels of plasma fibrinogen and D-dimer are significantly higher than in the euthyroidic subjects [27].…”